TARS · Tarsus Pharmaceuticals, Inc. · Executive Compensation

$79.31 -1.81 (-2.23%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$3.48B

43.88M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Bobak Azamian	M.D., Ph.D. President, Chief Executive Officer and Board Chairman	$726,333	—	$2,648,284	$2,651,487	$555,700	$36,175	$6,617,979
Jeffrey S. Farrow	Chief Financial Officer and Chief Strategy Officer	$541,667	—	$893,961	$895,011	$264,900	$82,078	$2,677,617
Seshadri Neervannan	Chief Operating Officer	$547,000	—	$893,961	$895,011	$267,300	$24,900	$2,628,172
Bryan Wahl	M.D., J.D.	$500,833	—	$893,961	$895,011	$245,500	$24,900	$2,560,205

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Bobak Azamian	M.D., Ph.D. President, Chief Executive Officer and Board Chairman	$673,400	—	$3,370,153	$3,267,692	$532,800	$52,147	$7,896,192
Jeffrey S. Farrow	Chief Financial Officer and Chief Strategy Officer	$520,833	—	$1,168,959	$1,133,398	$307,200	$102,536	$3,232,926
Seshadri Neervannan	Chief Operating Officer	$527,333	—	$1,168,959	$1,133,398	$311,300	$53,699	$3,194,689
Aziz Mottiwala	Chief Commercial Officer	$492,633	—	$1,168,959	$1,133,398	$292,500	$51,372	$3,138,862
Elizabeth Yeu-Lin	Chief Medical Officer	$78,182	$25,000	$1,399,928	$1,548,238	—	$53,509	$3,104,857

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jeffrey S. Farrow	Chief Financial Officer and Chief Strategy Officer	$343,751	$100,000	$1,678,310	$1,590,572	$241,200	$37,997	$3,991,830
Bobak Azamian	M.D., Ph.D. President, Chief Executive Officer and Board Chairman	$619,500	—	$1,029,364	$1,017,968	$450,300	$13,200	$3,130,332
Leonard Greenstein	Chief Financial Officer	$202,100	—	$411,746	$893,298	$71,552	$399,883	$1,978,579
Seshadri Neervannan	Chief Operating Officer	$500,000	—	$494,095	$488,623	$246,000	$13,200	$1,741,918

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Bobak Azamian	M.D., Ph.D. President, Chief Executive Officer and Board Chairman	$590,000	—	$876,822	$2,077,378	$324,500	$47,580	$3,916,280
Jose Trevejo	M.D., Ph.D Chief Medical Officer	$403,333	$150,000	$606,054	$1,642,347	$176,000	$40,057	$3,017,791
Bryan Wahl	M.D., J.D. General Counsel and Secretary	$420,000	—	$1,034,621	$880,641	$168,000	$31,087	$2,534,349

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Bobak Azamian	M.D., Ph.D. President, Chief Executive Officer and Board Chairman	$550,000	—	—	$6,029,589	$269,500	$21,634	$6,870,723
Dianne Whitfield	MSW Chief Human Resources Officer	$358,636	$194,599	—	$2,628,804	—	$25,665	$3,207,704
Bryan Wahl	M.D., J.D. General Counsel and Secretary	$345,000	$50,000	—	$2,081,421	$141,408	$9,113	$2,626,942

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Bobak Azamian	M.D., Ph.D. President, Chief Executive Officer and Director	$437,000	$211,484	—	$1,847,092	—	$14,820	$2,510,396
Seshadri Neervannan	Ph.D. . Chief Operating Officer	$199,621	$85,248	—	$1,926,633	—	$2,175	$2,213,677
Leo M. Greenstein	Chief Financial Officer	$256,023	$147,437	—	$418,703	—	$13,280	$835,443

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Bobak Azamian	M.D. Ph.D. President, Chief Executive Officer and Director	$300,000	$116,137	—	—	—	—	$416,137

Executive changes

Person	Role	Change	Effective	Filed
David E.I. Pyott	Class III director	Appointed	2026-02-18	2026-02-18
Rosemary Crane	member of the Board of Directors	Resigned	2025-01-17	2025-01-17
Elizabeth Yeu, M.D.	member of the Company's board of directors	Resigned	2024-11-04	2024-11-05
Elizabeth Yeu, M.D.	Chief Medical Officer	Appointed	2024-11-04	2024-11-05

Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 94 filings 94 filers Visit website Investor relations